Monthly statement of changes in securities of share issuers and issuers of Hong Kong depositary securities listed in accordance with chapter 19b of the Listing Rules
As of February 28, 2022 status: newly submitted
To: Hong Kong Exchanges and Clearing Limited
Company name: Shanghai Haohai Biological Technology Co.Ltd(688366) (the “company”) (a joint stock limited company incorporated in the people’s Republic of China)
Date of submission: March 3, 2022
1. Changes in authorized / registered share capital
1. Class of shares ordinary shares class of shares H shares listed on the stock exchange of Hong Kong (Note 1) yes
Stock code 06826 description H shares
Number of authorized / registered shares par value authorized / registered share capital
Balance at the end of last month: 38022100 RMB 1 increase / decrease (-) 0 RMB 0 balance at the end of this month 38022100 RMB 1 RMB 380221002 Class of shares common stock class of shares A-Shares listed on the stock exchange of Hong Kong (Note 1) no
Stock code n / a description A shares (Shanghai Stock Exchange science and innovation board, stock code: Shanghai Haohai Biological Technology Co.Ltd(688366) )
Number of authorized / registered shares par value authorized / registered share capital
Balance at the end of last month: 137800000 RMB 1 increase / decrease (-) 0 RMB 0 balance at the end of this month 137800000 RMB 1 RMB 137800000 Total authorized / registered capital at the end of this month: RMB 175822100
remarks:
As the company is incorporated in the people’s Republic of China, the concept of “authorized share capital” does not apply to the company. The above information refers to the “registered share capital” of the company.
II. Changes in issued shares
1. Class of shares ordinary shares class of shares H shares listed on the stock exchange of Hong Kong (Note 1) yes
Stock code 06826 description H shares
Balance at the end of last month: 38022100
Increase / decrease (-) 0
Balance at the end of this month: 38022100
2. Class of shares common stock class A shares listed on the stock exchange of Hong Kong (Note 1) no
Stock code n / a description A shares (Shanghai Stock Exchange science and innovation board, stock code: Shanghai Haohai Biological Technology Co.Ltd(688366) )
Balance at the end of last month: 137800000
Increase / decrease (-) 0
Balance at the end of this month: 137800000
Page 3 of 7 V 1.0.1iii Details of changes in issued shares (a) Share options (under the issuer’s share option plan) do not apply (b) Warrants promising to issue shares of issuers to be listed do not apply (c) Convertible notes (i.e. converted into shares of the issuer to be listed) do not apply (d) Any other agreement or arrangement entered into for the issuance of the issued shares to be listed, including options (but excluding options issued under the share option plan), does not apply (E) Other changes in issued shares
1. Class of issuable shares (notes 5 and 6) class of ordinary shares H shares issuable shares will be listed on the stock exchange of Hong Kong (notes 1, 5 and 6) yes
Stock code of issuable shares (if listed on the stock exchange of Hong Kong) (notes 1, 5 and 6) 06826
Price (if applicable) date of issuance and allotment the new share capital of the issuer thus issued within the current month on the date of adoption of the general meeting of shareholders at the end of the month may be issued by the issuer (notes 5 and 6) (if applicable) number of shares (E) number of new shares
Money price
1). Total number of shares repurchased from June 11, 2021 to 1692100 e (ordinary shares H shares):
Note: on February 28, 2022, 1692100 H shares repurchased by the company on December 30, 2021 and during the month ended January 31, 2022 have not been cancelled.
Total increase / decrease (-) of common stock H shares in this month (i.e. the sum of items a to e)
Page 4 of 7 V 1.0.1
4. Information about Hong Kong depositary securities (ADSS) is not applicable
Page 5 of 7 V 1.0.1v Confirmation we hereby confirm that, to the best of our knowledge and belief, each security issued by the issuer in this month (as described in Parts III and IV but not disclosed in the statement published in accordance with rule 13.25a of the main board rules / rule 17.27a of the gem rules) has been duly authorized and approved by the board of directors of the issuer, (I) where the issuer is entitled to receive all the listed funds (Note 2); (II) the rules governing the listing of securities on the stock exchange of Hong Kong Limited
